- Home
- ALLO vs ACB Comparison
ALLO vs ACB Comparison
Compare ALLO & ACB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALLO
- ACB
- Stock Information
- Founded
- ALLO 2017
- ACB 2013
- Country
- ALLO United States
- ACB Canada
- Employees
- ALLO N/A
- ACB N/A
- Industry
- ALLO Biotechnology: Biological Products (No Diagnostic Substances)
- ACB Pharmaceuticals and Biotechnology
- Sector
- ALLO Health Care
- ACB Health Care
- Exchange
- ALLO Nasdaq
- ACB Nasdaq
- Market Cap
- ALLO 277.8M
- ACB 294.7M
- IPO Year
- ALLO 2018
- ACB N/A
- Fundamental
- Price
- ALLO $1.40
- ACB $6.09
- Analyst Decision
- ALLO Strong Buy
- ACB Hold
- Analyst Count
- ALLO 9
- ACB 1
- Target Price
- ALLO $8.44
- ACB N/A
- AVG Volume (30 Days)
- ALLO 2.6M
- ACB 852.5K
- Earning Date
- ALLO 08-06-2025
- ACB 08-06-2025
- Dividend Yield
- ALLO N/A
- ACB N/A
- EPS Growth
- ALLO N/A
- ACB N/A
- EPS
- ALLO N/A
- ACB 0.07
- Revenue
- ALLO N/A
- ACB $222,964,332.00
- Revenue This Year
- ALLO N/A
- ACB $27.84
- Revenue Next Year
- ALLO N/A
- ACB $11.50
- P/E Ratio
- ALLO N/A
- ACB $92.82
- Revenue Growth
- ALLO N/A
- ACB 20.72
- 52 Week Low
- ALLO $0.86
- ACB $3.42
- 52 Week High
- ALLO $3.78
- ACB $7.20
- Technical
- Relative Strength Index (RSI)
- ALLO 56.45
- ACB 70.93
- Support Level
- ALLO $1.27
- ACB $5.36
- Resistance Level
- ALLO $1.51
- ACB $6.25
- Average True Range (ATR)
- ALLO 0.11
- ACB 0.23
- MACD
- ALLO 0.04
- ACB 0.05
- Stochastic Oscillator
- ALLO 77.55
- ACB 85.45
About ALLO Allogene Therapeutics Inc.
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.
About ACB Aurora Cannabis Inc.
Aurora Cannabis, headquartered in Edmonton, Canada, cultivates and sells medicinal and recreational cannabis through a portfolio of brands that includes Drift, San Rafael '71, Daily Special, Whistler, Being, and Greybeard. Although the company primarily operates in Canada, it has expanded internationally through medical cannabis exporting agreements.